Saquinavir: An HIV proteinase inhibitor

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 305-317

  Bragman, Keith ^b  

^a Parc Club des Tanneries   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INTEGRASE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; ZALCITABINE; ZIDOVUDINE;

ADULT; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG POTENTIATION; DRUG SAFETY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 2;

EID: 0029916638     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_28     Document Type: Conference Paper

References (26)

1. Robins T, Plattner J. HIV Proteinase inhibitors: their anti-HIV activity and potential role in treatment. J Acquir Immune Defic Syndr 1993;6:162-170.
2. Roberts NA, Matin JA, Kinchington D, et al. Rational design of peptide based HIV proteinase inhibitors. Science. 1990;248:358-361.
3. Navia MA, Fitzgerald PMD, McKever BM, et al. Three dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1 Nature 1989;337:615-20.
4. Criag JC, Duncan IB, Hockely D, Grief C, Roberts NA, Mills JS. Antiviral properties of Ro 31-8959, an inhibitor of human immunodeficiency virus (HIV) proteinase. Antiviral Res 1991;16:295-305.
5. Johnson VA, Merrill P, Chou TC, Hirsch MS. Human immunodeficiency virus type 1 (HIV-1) inhibitory interactions between proteinase inhibitor Ro 31-8959 and zidovudine, 2′3′-dideoxycytidine, or recombinant interferon alfa against zidovudine-sensitive or resistant HIV-1 in vitro. J Infect Dis 1992;166:1143-6.
6. Craig JC, Duncan IB, Whittaker L, Roberts NA. Antiviral synergy between inhibitors of HIV proteinase and reverse transcriptase. Antiviral Chemistry and Chemotherapy 1990;4:161-166.
7. •). Antiviral Chem Chemother 1991;2:181-186.
8. Kramer RA, Schaber MD, Slalka AM, Ganguly K, Wong-Stall F, Reddy EP. HTLA III gag protein is processed in yeast cells by the virus po1 proteinase. Science 1986;231:1580-1584.
9. Johnson VA, Walker BD, Barlow MA, Paradis TJ, Chou TC, Hirsch MS. Synergistic inhibition of human immunodeficiency virus type 1 and 2 replication in vitro by castanospermine and 3′-azido-3′-deoxythymidine. Antimicrob Agents Chemother 1989;33:53-57.
10. Johnson VA, Barlow MA, Chou TC, Fischer RA, Walker BD, Hirsch MS, Schooley RT. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by recombinant soluble CD4 and 3′-azido-3′-azido-3′deoxythymidine. J Infect Dis 1989;159:837-844.
11. Mazzuli T, Hirsch MS. Combination Therapy for HIV Infection. In Mills J, Corey L (editors), Antiviral Chemotherapy, Vol 3. PTR Prentice Hall, 1993;385-416.
12. Balzarini J, Herdewijn P, de Clercq E. Differential patterns of intracellular metabolism of 2′,3′-didehydro-2′,3′-dideoxythymidine and 3′-azido-2′,3′-dideoxythimidine, two potent anti-human immunodeficiency virus compounds. J Biol Chem 1989;264:6127-6133.
13. Meng TC, Fischl MA, Boota AM, Spector S, Bennett D. Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodefficiency virus infection. A phase I/II study. Annals Int Med 1992;116:13-20.
14. Richman DD, Kornbluth RS, Carson DA. Failure of dideoxynucleosides to inhibit human immunodeficiency virus replication in cultured human macrophages. J Exp Med 1987;166:1144-1149
15. Craig J, Whittaker L, Duncan I, Roberts N. In vitro anti-HIV and cytotoxicological evaluation of the triple combination: AZT and ddC with HIV proteinase inhibitor saquinavir (Ro 31-8959). Antiviral Chemistry and Chemotherapy. 1994;5:380-386.
16. D'Aquila R, Johnson V, Welles S et at. Zidovudine resistance and HIV-1 disease progression during antiretroviral therapy. Ann Int Med 122(6):401-407.
17. Richman DD. HIV drug resistance. AIDS Res Human Retrovirus 1992;8:1065-1071.
18. Craig JC, Whittaker L, Duncan IB, Roberts NA. Jn vitro resistance to an inhibitor of HIV proteinase (Ro 31-8959) relative to inhibitors of reverse transcriptase (AZT and TIBO). Antiviral Chem Chemother. 1993;4:335-339.
19. Jacobsen H, Yasargil K, Winslow D, Craig J, Krohn A, Duncan I, Mous J. Characterization of human immunodeficiency virus TYPE 1 mutants with decreased sensitivity to protease inhibitor Ro 31-8959. Virology 1995;206:527-534.
20. Otto MJ, Garber S, Winslow DL, Reid CD, Aldrich P, Jadhar PK, Patterson CE, Hodge CN, Cheng YSE. In vitro isolation and identification of human immunodeficiency virus (HIV) variants with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993;90:7543-7547.
21. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN Safety and activity of saquinavir in HIV infection. The Lancet 1995;345:952-955.
22. Delfraissy JF, Sereni D, Brun-Vezinet F, Dussaix E, Krivine A, Dormont J et al. A phase I-II dose ranging study of the safety and activity of Ro 31-8959 (HIV-proteinase inhibitor) in previously Zidovudine (ZDV) treated HIV-infected individuals IXth International Conference on AIDS, Berlin, June 1993, Abstract, WS-B26-3.
23. Vella S. (1995) submitted for publication.
24. Basset R, Schoenfeld D, Collier A. Double blind, randomized Phase II study of Ro 31-8959 + zidovudine vs zidovudine + zalcitabine vs Ro 31-8959 +zidovudine + zalcitabine, ACTG 229 Executive Summary, May 26, 1994.
25. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantitation of human immunodeficiency virus type 1 RNA in plasma: Application to acute retroviral infection. J Clin Microbiol. 1994;32:292-300.
26. Jacobsen H. (unpublished observations, 1995).